Month: December 2023

Release – 10,000 L/day DLE Pilot Plant Ships to LithiumBank’s Calgary Facility

Posted on by cpatches

Research, News, and Market Data on LBNKF

Calgary, Alberta. December 11, 2023 – LithiumBank Resources Corp. (TSX-V: LBNK) (OTCQX: LBNKF) (“LithiumBank” or the “Company”) is pleased to announce that the G2L Greenview Resources Inc. (“G2L”) Direct Lithium Extraction (DLE) pilot plant is now in transit to LithiumBank’s Calgary facility. Once completed, the facility will have capacity to process up to 10,000 L/d of brine and yield up to 3 kg/d LCE.  Commencing in early 2024, several piloting campaigns are planned as the Boardwalk Project advances into its feasibility studies phase of development. The Company also anticipates that the facility will accelerate the development of the Company’s Park Place, Estevan, South, and Kindersley properties.

The pilot plant has been constructed in Australia by Clean TeQ Water on the behalf of G2L and is based on G2L’s Continuous Direct Lithium Extraction (cDLE®) technology.  As seen in recent testwork results (Reported Nov. 22, 2023), the cDLE® process utilizes an ion exchange material (sorbent) designed to selectively extract lithium from the brine while rejecting most contaminants. In the context of the Boardwalk Project, the configuration of the pilot adsorption and elution stages has been purposefully designed to maximize extraction of lithium from the brine.  Similarly, the selectivity of the sorbent and elution chemistry allows strong rejection of typical impurities in the brine such as sodium, calcium and chloride. This results in a clean, lithium-rich concentrate suitable for further refining.

At the facility in Calgary, the cDLE® process will demonstrate the cost and process advantages of using common industrial reagents such as quicklime and sulfuric acid. The operating cost benefits of this change in reagent suite will be quantified in an updated Boardwalk Project Preliminary Economic Assessment. Senior process engineers from G2L will head up the installation of the pilot and the first 100 hours of processing. G2L will continue to lend support throughout the entire piloting program which is intended to last up to 18 months following the first 100 hours of operation.

With a processing capacity of up to 10,000 L/d of brine, the Calgary facility will represent one of the largest DLE pilot plants in North America. The pilot plant represents an approximate 1:5,000 scale to the future, commercial production modules which is consistent with scale-up factors used in other hydrometallurgical processes.  Within the pilot plant, sufficiently large ion exchange equipment has been installed to permit direct scale-up of these process steps to the commercial plant, accelerating the Boardwalk Project development.

During operation, the pilot plant will be targeting one of the industry’s highest lithium recoveries. This is seen as achievable for the Boardwalk project given the project’s careful staging of adsorption and elution contactors, along with the characteristics of the sorbent. Specifically, experiences from industrial ion exchange processes used for the recovery of precious (gold) and energy (uranium) metals have been leveraged in formulating the Boardwalk DLE flowsheet. This formulation included a trade-off assessment of lithium recovery and capital cost which was undertaken for the purposes of the upcoming updated PEA. As a result, the pilot plant will assess the performance of five contactor stages with results to follow in the PEA.

Figure 1: LithiumBank’s pilot plant as shown in G2L’s manufacturing facility in Melbourne, Australia, prior to shipment.

Furthermore, G2L’s experience in pilot testing of continuous ion exchange for recovery of other metals, including nickel and cobalt, at a similar scale in similar pilot equipment, provides confidence that recovery using counter-current adsorption contactors can be predicted from laboratory scale test work.

The cDLE® pilot plant in transit is a variation of a pilot plant that was designed and constructed by the Clean TeQ Water technical team to extract nickel and cobalt by ion exchange from acid leached lateritic ore in the Sunrise Energy Metals project. The plant was run over several campaigns and the data were subsequently used for a Bankable Feasibility Study (BFS) on the production of battery-grade nickel and cobalt sulfates. The Boardwalk Project cDLE® plant uses the same basic configuration, with critical design changes incorporated to ensure maximum lithium extraction from the brine, and the production of a high purity eluate containing a high lithium concentration.

A video showing the cDLE® pilot plant prior to shipping to Calgary can be viewed below:

About LithiumBank Resources Corp.

LithiumBank Resources Corp. (TSX-V: LBNK) (OTCQX: LBNKF), is a publicly traded lithium company that is focused on developing its two flagship projects, Boardwalk and Park Place, in Western Canada. The Company holds 2,480,196 acres of brownfield & exploration lithium brine permits, across 3 districts in Alberta and Saskatchewan. In May 2023, LithiumBank completed an initial robust preliminary economic assessment of its Boardwalk project that targets a 31,350 TPA operation with a pre-tax USD $2.7B NPV and a 21.6% IRR with the potential for a number of near term enhancements. The Company will continue to de- risk its assets through detailed geological modelling and advanced engineering.

For more information see the Company’s Boardwalk Lithium Brine Project Preliminary Economic Assessment Technical report entitled “Preliminary Economic Assessment (PEA) for LithiumBank Resources Boardwalk Lithium-Brine Project in West- Central Alberta, Canada” effectively dated June 16, 2023 filed on  SEDAR+ (www.sedarplus.ca) on June 23, 2023 and on the Company’s website (www.lithiumbank.ca).
 
Mineral resources are not mineral reserves and do not have demonstrated economic viability. There is no guarantee that all or any part of the mineral resource will be converted into a mineral reserve. The estimate of mineral resources may be materially affected by geology, environment, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues. A preliminary economic assessment is preliminary in nature as it includes a portion of inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves, and there is no certainty that the preliminary economic assessment will be realized.

About G2L Greenview Resources Inc.
 
Go2Lithium Inc. was formed in early 2023 as a 50/50 joint venture with Computational Geosciences Inc (CGI), a subsidiary of the Robert Friedland-chaired Ivanhoe Electric Inc. (NYSE:IE) and Clean TeQ Water (ASX:CNQ). Please see Clean TeQ’s case studies for additional information on their suite of water treatment and metal extraction technologies.

The scientific and technical disclosure in this news release has been reviewed and approved by Mr. Kevin Piepgrass (Chief Operations Officer, LithiumBank Resources Corp.), who is a Member of the Association of Professional Engineers and Geoscientists of Alberta (APEGA) and the Association of Professional Engineers and Geoscientists of the Province of British Columbia (APEGBC) and is a Qualified Person (QP) for the purposes of National Instrument 43-101. Mr. Piepgrass consents to the inclusion of the data in the form and context in which it appears.

Contact:
LithiumBank     
Rob Shewchuk
CEO & Director
rob@lithiumbank.ca
(778) 987-9767
 
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
 
Cautionary Statement Regarding Forward Looking Statements
 
This press release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including without limitation, statements regarding the completion of the Offering and the timing thereof, and the anticipated use of proceeds of the Offering are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” or occur. Forward-looking statements are based on certain material assumptions and analyses made by the Company and the opinions and estimates of management as of the date of this press release, including, but not limited to, that the Company will complete the Offering on the terms disclosed, that the Company will receive all necessary regulatory approvals for the Offering, that the Company will use the proceeds of the Offering as currently anticipated; and assumptions relating to the state of the financial markets for the Company’s securities. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, market volatility, unanticipated costs, changes in applicable regulations, and changes in the Company’s business plans. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

Comtech Telecommunications (CMTL) – Momentum Continues to Build

Posted on by cpatches


Monday, December 11, 2023

Comtech Telecommunications Corp. engages in the design, development, production, and marketing of products, systems, and services for advanced communications solutions in the United States and internationally. It operates in three segments: Telecommunications Transmission, Mobile Data Communications, and RF Microwave Amplifiers. The Telecommunications Transmission segment provides satellite earth station equipment and systems, over-the-horizon microwave systems, and forward error correction technology, which are used in various commercial and government applications, including backhaul of wireless and cellular traffic, broadcasting (including HDTV), IP-based communications traffic, long distance telephony, and secure defense applications. The Mobile Data Communications segment provides mobile satellite transceivers, and computers and satellite earth station network gateways and associated installation, training, and maintenance services; supplies and operates satellite packet data networks, including arranging and providing satellite capacity; and offers microsatellites and related components. The RF Microwave Amplifiers segment designs, develops, manufactures, and markets satellite earth station traveling wave tube amplifiers (TWTA) and broadband amplifiers. Its amplifiers are used in broadcast and broadband satellite communication; defense applications, such as telecommunications systems and electronic warfare systems; and commercial applications comprising oncology treatment systems, as well as to amplify signals carrying voice, video, or data for air-to-satellite-to-ground communications. The company serves satellite systems integrators, wireless and other communication service providers, broadcasters, defense contractors, military, governments, and oil companies. Comtech markets its products through independent representatives and value-added resellers. The company was founded in 1967 and is headquartered in Melville, New York.

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Momentum. The first quarter of fiscal 2024 was Comtech’s eighth consecutive quarter of sequential revenue increase and the second quarter of positive operating income, a substantial improvement, in our view. Net bookings were $185.6 million for a book-to-bill of 1.22x. Revenue visibility is now $1.7 billion, up from a prior $1.1 billion.

1Q24 Results. Revenue totaled $151.9 million, up 2.1% sequentially, within guidance. Y-o-Y revenue was up 15.8%. We were at $151 million. Adjusted EBITDA totaled $18.4 million, versus $10.7 million in 1Q23. We were at $17.1 million. Comtech reported a net loss of $3.3 million, or a loss of $0.11 per share, compared to a net loss of $12.8 million, or $0.46 per share last year. Adjusted EPS was $0.24 versus $0.16. We had forecast a net loss of $2.1 million, or a loss of $0.07 per share and adjusted EPS of $0.22.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

DLH Holdings (DLHC) – Fourth Quarter In-Line

Posted on by cpatches


Monday, December 11, 2023

DLH delivers improved health and readiness solutions for federal programs through research, development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,300 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to public health to improve the lives of millions. For more information, visit www.DLHcorp.com.

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

4Q Results. Revenue of $101.5 million was slightly above management’s revised guidance of $100 million, and up from $67.2 million in 4Q22. While the majority of the revenue increase was due to GRSi, which contributed $33.1 million, the Company did see organic growth. Due to the expected $7.7 million non-cash impairment charge, DLH reported a net loss of $2.6 million, or $0.18/sh compared to net income of $3.4 million, or EPS of $0.24/sh in 4Q22.

Non-GAAP. On a non-GAAP basis, DLH reported adjusted operating income of $7.8 million, adjusted EBITDA of $12.1 million, and adjusted net income of $2.3 million, or $0.16/sh in 4Q23, compared to $5.1 million, $7.0 million, and $3.7 million, or EPS of $0.26/sh, respectively, last year.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Vera Bradley (VRA) – Third Quarter Fiscal 2024 Results Mixed

Posted on by cpatches


Monday, December 11, 2023

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

3QFY24. Net revenue of $114.9 million, compared to $124.0 million in 3Q23, and below our estimate of $124 million. Gross margin improved to 54.8%, up 190 basis points y-o-y. Net income of $5.1 million, or $0.16/sh ($0.19/sh adjusted) compared to net income of $5.2 million, or $0.17/sh (adjusted of $0.20). We had forecasted net income of $4.5 million, or $0.14/sh.

Segments. VB Direct segment revenues totaled $72.3 million, a 9.7% decrease y-o-y. Comparable sales declined 8.2% in the third quarter, primarily driven by weakness in the outlet channel. VB Indirect segment revenues totaled $25.0 million, a 12.0% increase y-o-y, reflecting a significant one-time key account order in 3Q24. Pura Vida revenues totaled $17.7 million, an 18.3% decrease y-o-y, reflecting a decline in sales to wholesale accounts and a decline in ecommerce sales.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Occidental Petroleum Expands Presence in Permian Basin with $12 Billion CrownRock Acquisition

Posted on by cpatches

In a strategic move to bolster its presence in the prolific Permian Basin, Occidental Petroleum has reached an agreement to acquire CrownRock for a staggering $12 billion. This significant deal, part of a broader consolidation trend in the U.S. energy sector, positions Occidental to fortify its standing as the ninth-largest energy company in the U.S.

CrownRock, a major privately held energy producer operating in the Permian Basin, is currently developing a 100,000-acre position in the Midland Basin, a crucial segment spanning 20 counties in western Texas. The Midland Basin, contributing 15% of U.S. crude production in 2020, is a key focus for Occidental’s goal to increase its scale in the Permian.

The transaction is set to add a substantial 170,000 barrels of oil equivalent per day to Occidental’s production capabilities. Furthermore, with 1,700 undeveloped locations in the Permian, the deal positions Occidental for strategic expansion in a region vital to the nation’s energy landscape.

To finance this significant acquisition, Occidental plans to issue $9.1 billion in new debt, complemented by approximately $1.7 billion in common stock. Despite these financial obligations, Occidental remains committed to its goal of reducing its overall debt to below $15 billion, showcasing confidence in the long-term benefits of the CrownRock acquisition.

This move comes amidst a flurry of major deals in the energy sector, with ExxonMobil announcing a $60 billion acquisition of Pioneer Natural Resources and Chevron taking over Hess for $53 billion in recent months. Occidental’s acquisition of CrownRock underscores the ongoing consolidation trend, particularly in the Permian Basin, the largest oil-producing region in the U.S.

Occidental’s CEO, Vicki Hollub, emphasized the company’s dedication to managing its financial commitments. Despite a 10% drop in Occidental’s stock year-to-date, the acquisition of CrownRock marks the third major deal in the energy sector within a span of two months, highlighting Occidental’s determination to adapt and grow in a rapidly evolving industry.

Berkshire Hathaway, a major holder with about 26% of Occidental’s shares, was not involved in this particular deal. Occidental’s ticker symbol is OXY, and the company anticipates finalizing the CrownRock acquisition in the first quarter of 2024, adding another chapter to its dynamic expansion strategy.

This acquisition is a pivotal moment for Occidental Petroleum as it continues to navigate the evolving energy landscape, strategically positioning itself for future success in the Permian Basin.

Occidental Petroleum Corporation (NYSE: OXY), commonly known as Occidental, has a storied history dating back to its founding in 1920. Established in California, the company evolved from a small oil production venture into one of the largest independent oil and gas exploration and production companies globally. Over the years, Occidental has played a pivotal role in the energy industry, engaging in diverse operations such as oil and gas exploration, production, refining, and marketing. Known for its innovative technologies and strategic acquisitions, Occidental has expanded its reach across the Americas, the Middle East, and North Africa. The company’s commitment to responsible and sustainable energy practices aligns with its pursuit of operational excellence. As the ninth-largest energy company in the U.S., Occidental continues to navigate the dynamic energy landscape, adapting to industry trends and solidifying its position through strategic acquisitions, such as the recent $12 billion CrownRock deal, which reflects its dedication to growth and resilience in an ever-evolving market.

Explore other emerging growth energy companies on Noble Capital Markets’ Senior Analyst Michael Heim’s coverage list

Cigna and Humana Merger Unravels Amid Price Disputes, Cigna to Pursue Share Buyback

Posted on by cpatches

Cigna has reportedly withdrawn from a significant merger with Humana, citing failed negotiations on pricing as the primary reason, according to insider sources. The deal, if successful, would have propelled the combined entity’s value beyond $140 billion, positioning it as a major player in the insurance sector. The potential mega-deal would have undoubtedly faced scrutiny from regulators, especially in light of regulatory blocks on similar consolidations in the health insurance sector six years ago. Cigna, undeterred by the merger setback, has announced plans to repurchase $10 billion worth of shares, a move deemed by management as a value-enhancing use of capital given their belief that Cigna shares are currently undervalued.

Connecticut-based Cigna, whose shares rose 12.1% to $290.07 in premarket trading on Monday, is down approximately 22% this year, experiencing a 10% decline since late November when reports of the deal talks with Humana surfaced. The company remains open to the prospect of a future merger with Humana, asserting confidence in the deal’s regulatory feasibility despite the Biden administration’s stringent stance on mergers.

Both Cigna and Humana are significant players in the health insurance sector, each with distinct operations. Cigna, a global health service company, has a diversified portfolio covering insurance, pharmacy benefits, behavioral health, and related services. The company’s strategic decision to explore the sale of its Medicare Advantage business, which caters to government health insurance for individuals aged 65 and older, indicates ongoing efforts to refine its business focus.

On the other hand, Humana, a prominent health and well-being company, specializes in health insurance and wellness solutions. The potential merger with Cigna would have endowed the combined entity with increased scale, positioning it as a formidable competitor against larger U.S. health insurance players such as UnitedHealth Group and CVS Health.

As Cigna navigates the aftermath of the abandoned merger, the company’s shift towards share buybacks and potential bolt-on acquisitions aligning with its strategies reflects a strategic realignment. The health insurance landscape remains dynamic, and Cigna’s future moves, including a possible revisiting of a Humana combination, will undoubtedly shape the trajectory of both companies in this ever-evolving sector.

Get to know a selection of emerging growth biotechs by exploring Noble Capital Markets’ Senior Analyst Robert LeBoyer’s coverage list.

Macy’s Receives $5.8 Billion Buyout Offer, Sparks Increased Investor Interest

Posted on by cpatches

Arkhouse Management and Brigade Capital Management Extend a $5.8 Billion Lifeline to Struggling Macy’s Inc.

In a bold move to rescue the iconic retailer, Arkhouse Management and Brigade Capital Management have proposed a buyout offer of $5.8 billion for Macy’s Inc. This strategic move comes at a time when Macy’s has faced a challenging year, with slumping sales and increasing competition from online retailers.

The buyout offer values Macy’s at $21 per share, a significant premium compared to its recent close at just over $17 per share. Macy’s shares closed at a little over $17 on Friday, representing a 17% decline since the beginning of the year. However, the market responded positively to the news, with a 15% increase in premarket trading on Monday.

Despite the retailer’s efforts to revitalize its brick-and-mortar stores, Macy’s sales have seen a 7% year-over-year decline in the third quarter. The struggle against online competitors and changing consumer preferences has made Macy’s an attractive acquisition target for Arkhouse and Brigade.

Arkhouse, primarily focused on real estate investment, and Brigade Capital, an asset management firm, have expressed their willingness to consider a higher bid after conducting due diligence on Macy’s. This signals their confidence in the potential for a successful turnaround.

Macy’s, with 722 store locations across 43 states, Washington, DC, Puerto Rico, and Guam, has faced challenges for decades. The rise of online giants like Amazon and the dominance of big-box retailers such as Walmart and Target have eroded Macy’s market share. The company’s annual profit and sales forecast was revised in June after a slowdown in customer demand, prompting a candid acknowledgment from Macy’s CEO Jeff Gennette.

“The US consumer, particularly at Macy’s, pulled back more than we anticipated,” Gennette stated on an earnings call. Customers “reallocated” spending to food, essentials, and services, he added.

This acquisition bid follows a similar trend in the retail sector, as evidenced by Kohl’s facing takeover offers in 2022. The challenging economic landscape, marked by volatile interest rates and high inflation, has affected retailers across the board. While online spending proved robust during Black Friday and Cyber Monday, uncertainties remain about the strength of the holiday season, especially after several retailers issued cautious fourth-quarter outlooks.

As Macy’s evaluates the proposal, the retail landscape awaits the potential transformation that Arkhouse Management and Brigade Capital Management could bring to this iconic brand.

Pushing the Frontiers: Innovation and Investment in Organ Transplantation

Posted on by slightbourne@noblecapitalmarkets.com

The NobleCon19 panel discussion moderated by Nathan Cali, investment banker at Noble Capital Markets, on organ transplantation featured prominent figures in the field, including Dr. Karin Hehenberger, an organ transplant patient and founder of Lyfebulb, Dr. David Alexandre Gros, CEO of Eledon Pharmaceuticals, Dr. Muhammed Mohiuddin, director of the cardiac xenotransplantation program at the University of Maryland, and Dr. Pietr Witoski, surgery director of pancreatic and islet tranplant program at the University of Chicago. The discussion delved into their experiences, challenges in the organ transplant landscape, and revolutionary advancements, especially focusing on the concept of xenotransplantation.

Organ transplantation has come a remarkably long way since the first successful procedures in the 1950s and 60s. Yet there remain significant unmet needs and opportunities to further improve patient outcomes, quality of life, and access to these lifesaving procedures. At a presentation during NobleCon19, a panel of experts explored some of the latest breakthroughs and remaining challenges in areas ranging from immunosuppression to cross-species transplantation.

A Complex Treatment Paradigm

As patient-turned-advocate Dr. Karin Hehenberger related from personal experience, undergoing an organ transplant and living with a graft is filled with difficulties. The trauma of the surgery itself and needing immune-suppressing drugs just to avoid rejection deliver blows to physical health and mental wellbeing. This begins with a harrowing wait for a matching donor organ, continues through post-operative complications like infections, and extends for the rest of one’s life.

The panelists agreed the pressure on patients could be significantly reduced through innovation. More targeted immunosuppressants without harmful side effects would greatly improve quality of life after transplant surgery. Some emerging drug candidates like Eledon Pharmaceuticals Tegoprubart show early signs of progress on this front. There is also a global shortage of donor organs trailing far behind demand; new sources through xenotransplantation or regenerative medicine techniques could help resolve this shortage.

“We need a community where transplanted patients can come together, generate data, and advocate for change,” urged Dr. Hehenberger.

The valuable role of patient communities mirrors the interdisciplinary cooperation needed among the surgeons, specialists, social workers, and other caregivers that make organ transplantation successful. As Dr. Hehhenberger explained, the assessment process for transplant eligibility spans physical health, mental fitness, medication compliance, accessible transportation, and financial support. It is complex care with little margin for error.

An Evolving Market Landscape

Currently, the organ transplant market racks up over $5 billion in value each year and continues expanding at a steady pace. Much of this activity centers specifically around kidney transplants, where surgical innovations and public policy initiatives keep pushing the boundaries. As Dr. DA Gros noted, there are now a quarter million Americans living with a functioning kidney graft – proof of concept for an underappreciated treatment paradigm.

And yet, the surface has barely been scratched in terms of serving potential patients. Over half a million more remain tethered to dialysis as a stand-in for natural kidney function, with 125,000 added to this group annually in the U.S. alone. Dialysis generates its own burdens: decreased workplace productivity, infection risks, lower quality of life. From both humanitarian and financial viewpoints, empowering wider transition from dialysis to transplantation promises tremendous upside.

Experts on the panel targeted improved education around organ transplant options as a key opportunity. Many patients lack full information about the benefits transplant procedures can offer, or they confront social stigmas against this route. Policy revisions to widen access and increase support for lower-income patient communities could have an outsized impact as well.

Meanwhile, the business of organ transplantation continuously evolves. Major pharma companies like Bristol Meyers Squib remain heavily invested, yet a series of smaller players also drive momentum through novel immuno-therapy products. Audience members were encouraged to track firms like Aelix and Tacus for the next wave of clinical updates that will shape standard of care.

Pioneering the Future

Homing in on the future, speakers keyed in on barriers still to be conquered in transplantation medicine. While kidney procedures serve as a beachhead, there is a pressing need to expand reliable methods across more organ types while lengthening graft duration at the same time. This is no small task.

It will require rethinking conventional assumptions for a field that has relied predominantly on broad immune suppression since its inception. Some emerging biotech pipelines target specific T and B cell pathways implicated in chronic organ rejection, attempting to avoid toxicity associated with generalized immunosuppression. Early data hints at improved longevity for liver and heart grafts, but longer studies are still needed.

An even more radical solution highlighted by multiple panelists is the concept of xenotransplantation: introducing organs from other species like pigs into human patients. Recent demonstrations of human-pig heart and skin grafts saw patients survive months post-procedure compared to an anticipated span of days or weeks. The results electrified the transplant community given implications for essentially eliminating organ supply constraints.

That said, experts admit there are hurdles left to address before clinical adoption. Ethical quandaries exist around genetically modifying donor animals and infectious disease transmission risks from one species to another. Questions also persist about which immune pathways necessitate targeting for prolonged graft survival and how to refine the anti-rejection pharmaceutical regimens employed.

Signs point to countries with more flexible regulatory regimes as the likely springboards for refining xenotransplant methods and technology in the shorter-term. Yet the longer-term promise seems resoundingly clear. “If allowed, we will solve the organ shortage problem,” declared surgeon Dr. Peter Witoski when asked about outlook for the field.

A Call to Action

In closing the panel presentation, speakers underscored a sense of guarded optimism balanced with persistent unmet needs in transplantation medicine today. Limitations around donor organ supply and chronic graft failure continue exacting a real human toll, even if raw statistics showcase a steady rise in life-saving procedures overall.

It will take coordinated effort from policy makers, researchers, clinicians, investors and patient advocates to push new discoveries over the finish line – where they can impact the maximum number of lives. Key questions around optimal business models for novel therapeutics, data transparency, and equitable access are unlikely to solve themselves.

Yet the convergence of breakthrough technologies and innovative platforms for generating evidence, educating stakeholders and disseminating insights points toward a sea change for what the future may hold in this vital area of healthcare. The experts and audience members left the discussion around organ transplantation feeling energized to play their respective parts in driving that change.

Watch the webcast from The Organ Transplant presentation at NobleCon19 here

Release – Anticipation Ignites With the Unveiling of a New Bellwright Trailer at the Game Awards

Posted on by aweinsoff@channelchek.com

Research News and Market Data on SNAL

December 8, 2023 at 8:08 AM EST

With over 300,000 wishlist additions on Steam, Bellwright is poised to be a game-changer in the survival town building RPG genre

LOS ANGELES, Dec. 08, 2023 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail” or “the Company”), a leading, global independent developer and publisher of interactive digital entertainment, in collaboration with Donkey Crew, proudly presented a new trailer for its upcoming title, Bellwright, at The Game Awards. Renowned for its dedication to showcasing cutting-edge gaming experiences, this showcase comes a week after the exciting announcement of Bellwright’s debut in Steam Early Access in early 2024 and its successful feature on the PC Gaming Show: Most Wanted.

Key Highlights:

Trailer Debut: Snail captivated the audience with the mesmerizing story elements, “You Are The Bellwright” with visually appealing graphics, intricate crafting, and dynamic action and exploration elements. This open-world survival game introduces a medieval setting with a rich and compelling lore, distinguishing itself as a groundbreaking addition to Snail’s portfolio.

Wishlist Milestone: First introduced at the Steam’s Next Fest this summer, now with over 300,000 wishlists on Steam, Bellwright emerges as one of Snail’s most anticipated titles.

Snail’s expertise in the open-world survival gaming niche is exemplified by the strong install base and hours played of the ARK franchise. The unveiling of Bellwright, further underscores Snail’s commitment to pushing the boundaries of open-world survival gaming and solidifies the company’s reputation as a leader in creating immersive and engaging open-world experiences. Bellwright’s medieval backdrop and intricate lore demonstrates the versatility and depth of Snail’s prowess within this gaming genre.

Bellwright Key Features:

Survive and Explore: Engage in a challenging world where gathering, hunting, building, and crafting are essential for survival. Embark on a journey through the land to uncover its secrets and adventures, transcending the oppressive rule of the Crown and its Royal Army.

Conquer and Expand: Rise from a humble camp to become the leader of a rebellion. Strengthen your cause by improving relations with settlements, growing armies, and liberating regions from the Crown’s influence. Gain followers with unique knowledge, unlocking new resources to advance your town’s technologies.

Resource and Town Management: As you free villages from the Crown’s oppression, build, manage, and upgrade your outposts and towns. Organize your workers and train formidable soldiers, fostering the rebellion against the Crown.

Skill-Based Directional Combat: Choose from a diverse array of medieval weapons and armor, honing your unique style in directional combat. From swords and axes to heavy mauls and bows, showcase your skill in battle.

Army Command: Lead your armies strategically, employing cunning tactics to gain an advantage. Customize and train your troops to assert your dominance on the battlefield.

Deep Progression: Enhance your combat and survival skills, train your soldiers, and witness your workers evolve into master craftsmen. Each recruit brings unique knowledge, offering endless growth opportunities.

Story and Roleplay: Unravel family secrets, discover the truth behind the accused murder of the Prince, and navigate the mysteries of the kingdom as you expand your influence.

Early Access on Steam: The game’s Early Access phase on Steam will allow players to shape its development through valuable feedback.

“Bellwright is a testament to our unwavering dedication to crafting exceptional open-world survival experiences. Our success with the ARK franchise serves as a foundation for Bellwright, and we are eager to continue to bring innovation to the genre and share this new and captivating journey with our players.” – Jim Tsai, Chief Executive Officer of Snail, Inc.

Watch the Bellwright trailer here!

About Snail, Inc.

Snail is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs and mobile devices.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding Snail’s intent, belief or current expectations. These forward-looking statements include information about possible or assumed future results of Snail’s business, financial condition, results of operations, liquidity, plans and objectives. The statements Snail makes regarding the following matters are forward-looking by their nature: growth prospects and strategies; launching new games and additional functionality to games that are commercially successful; expectations regarding significant drivers of future growth; its ability to retain and increase its player base and develop new video games and enhance existing games; competition from companies in a number of industries, including other game developers and publishers and both large and small, public and private Internet companies; its relationships with third-party platforms; expectations for future growth and performance; and assumptions underlying any of the foregoing.

Contacts:

Investors:
investors@snail.com

Press:
media@snail.com 

Release – Comtech Announces Results for its First Quarter of Fiscal 2024 and Provides Second Quarter Fiscal 2024 Financial Targets

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CMTL

BY THE COMTECH EDITORIAL TEAM – DEC 7, 2023 | 2 MIN READ

Q1 Consolidated Net Sales Up 2.1% Sequentially to $151.9 Million

Q1 Consolidated Operating Income Up 86.2% Sequentially to $2.1 Million

Q1 Consolidated Adjusted EBITDA of $18.4 Million, or 12.1% of Consolidated Net Sales

MELVILLE, N.Y. – December 7, 2023– Comtech (NASDAQ: CMTL) today announced its first quarter fiscal 2024 financial results and provided its second quarter fiscal 2024 financial targets in a letter to shareholders which is now posted to the Investor Relations section of Comtech’s website.

Investors are invited to access the first quarter fiscal 2024 shareholder letter at its web site at comtech.com/investors/. A copy of the letter will also be filed with the Securities and Exchange Commission in a Form 8-K.

Comtech also intends to host a previously scheduled earnings conference call at 5:00PM ET today. Individuals can access the conference call by dialing (800) 579-2543 (domestic) or (785) 424-1789 (international) and using the conference I.D. of “Comtech.” A replay of the conference call will be available for two weeks by dialing (888) 219-1269 or (402) 220-4945. A live webcast of the call is also available at comtech.com/investors/.

About Comtech

Comtech Telecommunications Corp. is a leading global technology company providing terrestrial and wireless network solutions, next-generation 9-1-1 emergency services, satellite and space communications technologies, and cloud native capabilities to commercial and government customers around the world. Our unique culture of innovation and employee empowerment unleashes a relentless passion for customer success. With multiple facilities located in technology corridors throughout the United States and around the world, Comtech leverages our global presence, technology leadership, and decades of experience to create the world’s most innovative communications solutions.For more information, please visit www.comtech.com.

Forward-Looking Statements

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward- looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings.

PCMTL

Investor Relations

Maria Ceriello

investors@comtech.com

Release – ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ZVSA

Dec 7, 2023

  • Diabetic kidney disease (DKD), which affects around 240 million people with Type 2 diabetes worldwide, is the leading cause of end-stage renal disease, which requires dialysis or kidney transplant for survival.
  • The article published in Alternative Therapies demonstrates that plasma NLRP3 inflammasomes and their resulting proinflammatory cytokines are significantly elevated in early-stage DKD and that levels progressively increase as kidney function worsens, with highly significant elevations (p<0.01) at each stage of disease.
  • Data suggest that early DKD intervention with inflammasome inhibitors has potential to attenuate disease progression.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which inhibits multiple inflammasome pathways (including the inflammasome NLRP3 pathway) to attenuate initiation and perpetuation of damaging inflammation that is pathogenic in DKD and other inflammatory diseases.

WESTON, Fla., Dec. 07, 2023 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases, announces publication of an article in the peer-reviewed journal, Alternative Therapies, demonstrating that plasma NLRP3 inflammasomes and their resulting proinflammatory cytokines are significantly elevated in early-stage DKD and that levels progressively increase as kidney function worsens.

In the paper titled, “Correlation Between Plasma NLRP3, IL-1β, and IL-18 and Diabetic Nephropathy in Patients With Type 2 Diabetes,” the authors evaluated the plasma of 152 patients with type 2 diabetes and DKD stratified by stage of disease (stages 1-5) and 30 patients with type 2 diabetes without kidney disease who serve as controls. Following are key findings reported in the paper:

  • Plasma levels of NLRP3 and proinflammatory cytokines, IL-1β, and IL-18, were significantly higher than controls in patients in each of the 5 stages of DKD, with progressively higher levels as kidney disease progressed (p<0.01).
  • NLRP3, IL-1β, and IL-18 levels positively correlated with DKD stage (p= 0.01), based on the Spearman correlation analysis.
  • These data are consistent with other studies demonstrating that inflammation has an important role in the development and progression of DKD.

To read the article, Click Here.

“The research published in Alternative Therapies reinforces the role of inflammasome-driven inflammation in development and progression of DKD, the leading cause of end-stage kidney disease, which requires dialysis or kidney transplant for survival,” commented Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President. “Although substantial progress has been made in slowing progression of DKD with introduction of ACE inhibitors, ARBs, and most recently SGLT2 inhibitors, patients are still progressing to end-stage renal disease. The data published in Alternative Therapies suggest that early DKD intervention with inflammasome inhibitors has potential to help attenuate disease progression.”

About Inflammasome ASC Inhibitor IC 100

IC 100 is a novel humanized IgG4 monoclonal antibody that inhibits the inflammasome adaptor protein ASC. IC 100 was designed to attenuate both initiation and perpetuation of the inflammatory response. It does so by binding to a specific region of the ASC component of multiple types of inflammasomes, including NLRP1, NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100 binds to ASC monomers, inhibiting inflammasome formation, thereby blocking activation of IL-1β early in the inflammatory cascade. IC 100 also binds to ASC Specks, both intracellularly and extracellularly, further blocking activation of IL-1β and the perpetuation of the inflammatory response that is pathogenic in inflammatory diseases. Because active cytokines amplify adaptive immunity through various mechanisms, IC 100, by attenuating cytokine activation, also attenuates the adaptive immune response. To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here.

About ZyVersa Therapeutics, Inc.

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa’s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa’s planned preclinical and clinical trials; the timing of the availability of data from ZyVersa’s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa’s plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa’s product candidates; ZyVersa’s commercialization, marketing and manufacturing capabilities and strategy; ZyVersa’s ability to protect its intellectual property position; and ZyVersa’s estimates regarding future revenue, expenses, capital requirements and need for additional financing.

New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

Corporate and IR Contact:
Karen Cashmere
Chief Commercial Officer
kcashmere@zyversa.com
786-251-9641        

Media Contacts
Tiberend Strategic Advisors, Inc.
Casey McDonald
cmcdonald@tiberend.com
646-577-8520

Dave Schemelia
dschemelia@tiberend.com
609-468-9325

Defense Metals Corp. (DFMTF) – Observations from the Phase II Pit Geotechnical Drilling Program

Posted on by cpatches


Friday, December 08, 2023

Defense Metals Corp. is a mineral exploration and development company focused on the acquisition, exploration and development of mineral deposits containing metals and elements commonly used in the electric power market, defense industry, national security sector and in the production of green energy technologies, such as, rare earths magnets used in wind turbines and in permanent magnet motors for electric vehicles. Defense Metals owns 100% of the Wicheeda Rare Earth Element Property located near Prince George, British Columbia, Canada. Defense Metals Corp. trades in Canada under the symbol “DEFN” on the TSX Venture Exchange, in the United States, under “DFMTF” on the OTCQB and in Germany on the Frankfurt Exchange under “35D”.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase II drilling program. Defense Metals completed Phase II open pit diamond core and sonic infrastructure geotechnical drilling. The program consisted of six diamond drill holes totaling 1,182 meters within the Wicheeda rare earth element (REE) deposit pit shell, inclusive of four open pit geochemical drill holes totaling 920 meters, and two near-mine exploration holes totaling 262 meters. Nine sonic overburden drill holes, and 14 test pits designed to help characterize the soil subsurface and bedrock foundations of future waste rock storage, contact water pond, crusher, processing plant, and tailings storage facility locations were also completed. A final Phase 3 drilling program will entail 10 sonic overburden drill holes and three test pits.

Successful outcomes. South and west pit wall drill holes WI23-81 and WI23-82 intersected significant widths of visibly REE mineralized dolomite carbonatite. Hole WI23-82 drilled into the west pit wall of the Wicheeda Deposit tested a new ground radiometric anomaly. Assay results are pending.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Saga Communications (SGA) – Compelling Total Return Potential

Posted on by slightbourne@noblecapitalmarkets.com

Friday, December 08, 2023

Saga Communications, Inc. is a broadcast company whose business is primarily devoted to acquiring, developing and operating radio stations. Saga currently owns or operates broadcast properties in 27 markets, including 79 FM and 33 AM radio stations. Saga’s strategy is to operate top billing radio stations in mid sized markets, defined as markets ranked (by market revenues) from 20 to 200. Saga’s radio stations employ a myriad of programming formats, including Active Rock, Adult Album Alternative, Adult Contemporary, Country, Classic Country, Classic Hits, Classic Rock, Contemporary Hits Radio, News/Talk, Oldies and Urban Contemporary. In operating its stations, Saga concentrates on the development of strong decentralized local management, which is responsible for the day-to-day operations of the stations in their market area and is compensated based on their financial performance as well as other performance factors that are deemed to effect the long-term ability of the stations to achieve financial objectives. Saga began operations in 1986 and became a publicly traded company in December 1992. The stock trades on NASDAQ under the ticker symbol “SGA”.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Announces a hefty special dividend. The company announced that it declared a special cash dividend of $2.00 per share to be paid on January 12, 2024 to shareholders on record December 20, 2023. The aggregate amount of the special dividend of $12.5 million will be paid from its sizable cash position. We believe that the announcement reflects the company’s confidence in its favorable fundamental outlook and significantly strong financial position.

Strong balance sheet. As of Sept. 30, the company had $31.2 million in cash and no long term debt. As such, the company has a strong balance sheet that will be maintained following the special dividend payment. This recent dividend announcement follows its Board’s review of the appropriate level of cash to be maintained on its balance sheet, which will reduce cash and short term investments to roughly $25 million. 

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.